Immunology

免疫学

• 批准号: 10576845
• 负责人: Jeffrey S. Miller
• 金额: $ 4.85万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576845
• 关键词: Acceleration; Address; Adult; Antigens; Area; Autoimmune Responses; Award; Basic Science; Biology; Breast; Budgets; CD8-Positive T-Lymphocytes; Cancer Burden; Cancer Center; Cancer Center Support Grant; Categories; Cell Therapy; Cells; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Data; Development; Direct Costs; Disease; Doctor of Philosophy; Engineering; Faculty; Faculty Recruitment; Flow Cytometry; Foundations; Funding; Future; Goals; Grant; Growth; Hematopoietic Neoplasms; Immune Tolerance; Immune response; Immunity; Immunologic Memory; Immunology; Immunotherapy; Infection; Interleukin-15; Journals; Leadership; Link; Lung; Maintenance; Malignant Neoplasms; Memory; Minnesota; Minority; Modeling; Morbidity - disease rate; Myeloid Leukemia; National Cancer Institute; Natural Killer Cells; Nature; Paper; Patients; Peer Review; Phase I Clinical Trials; Pilot Projects; Play; Prostate; Publications; Publishing; Reagent; Research; Research Personnel; Resource Sharing; Resources; Role; Schools; Science; Scientific Advances and Accomplishments; Solid Neoplasm; Source; Specificity; T memory cell; Testing; Time; Training; Translating; Translation Process; Transplantation; United States National Institutes of Health; Veterinary Medicine; Work; anti-tumor immune response; cancer immunotherapy; chimeric antigen receptor; college; early phase clinical trial; experience; first-in-human; immune checkpoint blockade; immune system function; innovation; insight; medical schools; meetings; melanoma; member; mortality; mouse model; next generation; novel; novel therapeutics; pre-clinical; preclinical study; programs; research clinical testing; side effect; subcutaneous; success; tool; translational pipeline; trispecific killer engager; tumor; working group

Immunology Program Summary The overarching goal of the Immunology Program is to define the basic mechanisms that control immunity in order to develop and optimize immunotherapies that generate a specific and durable anti-tumor immune response. To achieve this goal, we have strong research themes in place focused on the following Aims: 1) To elucidate the mechanisms that control immune tolerance, 2) To understand the development and maintenance of immunological memory, and 3) To develop and optimize cancer immunotherapies. The Immunology Program is led by Yoji Shimizu, PhD, and new co-leader, Jeffrey Miller, MD. Drs. Shimizu and Miller work collaboratively to accelerate Immunology Program research findings through the translational pipeline. Dr. Shimizu works with Immunology Program members to move high-impact and innovative basic research advances into cancer-relevant models and preclinical studies, and Dr. Miller bridges the basic science discoveries to resources within the Masonic Cancer Center in order to ultimately translate Immunology Program research findings into phase 1 clinical trials. The Program has 22 members, representing 9 departments and 3 schools or colleges (Medical School, College of Science and Engineering, and College of Veterinary Medicine). For the last budget year, these members were supported by $2.5 million in direct costs from the National Cancer Institute; funding from all peer-reviewed sources totaled $7.6 million in direct costs. Since 2013, Program members have published 354 papers (21% in journals with an impact factor >10), 24% of which resulted from intraprogrammatic collaborations, 23% from interprogrammatic collaborations, and 80% from external collaborations. Since 2013, 74 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 203 patients. Access to Masonic Cancer Center Shared Resources, particularly Flow Cytometry and Translational Cell Therapy, is essential to the success of the Immunology Program. The Masonic Cancer Center has also enhanced Program activities through new faculty recruitments and funding of 4 pilot projects that resulted in 3 NCI-funded grants and a total ROI of $4.5M. The MCC supported and funded 21 monthly seminars that included 5 invited external speakers. Extensive intraprogrammatic and interprogrammatic interactions are enhanced by regular research-in-progress supergroup meetings, a faculty-only data club, a journal club, and an annual retreat sponsored by the Masonic Cancer Center. Program members also play a leadership role in training the next generation of cancer researchers. The Immunology Program research is aligned with the Masonic Cancer Center's strategic Scientific Priority for Growth (SPG1) to expand recent discoveries in immunotherapy and cellular therapeutics to include solid tumors. Furthermore, the Program's research addresses the elevated rates of myeloid leukemia and melanoma in Minnesota as well as developing novel therapies to reduce cancer morbidity and mortality for the major cancer burdens in MN: prostate, breast, lung.

免疫学课程摘要 免疫学计划的首要目标是定义控制免疫的基本机制 为了开发和优化产生特异和持久的抗肿瘤免疫的免疫疗法 回应。为了实现这一目标，我们制定了强有力的研究主题，重点关注以下目标：1) 阐明免疫耐受的控制机制，2)了解免疫耐受的发生和维持 3)开发和优化癌症免疫疗法。免疫学 该项目由清水洋治博士和新任共同负责人、医学博士杰弗里·米勒领导。清水博士和米勒博士 通过翻译管道协作加速免疫学计划的研究成果。Dr。 清水与免疫学项目成员合作推动高影响力和创新性的基础研究 在癌症相关模型和临床前研究方面的进展，米勒博士架起了基础科学的桥梁 共济会癌症中心内部资源的发现，以最终翻译免疫学 将研究成果纳入第一阶段临床试验。该计划有22名成员，代表9名成员 系和3所学校或学院(医学院、理工学院和理工学院) 兽医)。在上一个预算年度，这些成员得到了250万美元的直接费用支持 来自国家癌症研究所；来自所有同行审查来源的资金总计760万美元的直接成本。 自2013年以来，计划成员发表了354篇论文(21%发表在影响因子为10的期刊上)，24% 这是由方案内协作导致的，23%来自方案间协作，80% 来自外部合作。自2013年以来，所有临床研究类别的74项临床试验都是在 这一规划领域已经积累了203名患者。访问共济会癌症中心共享资源， 尤其是流式细胞术和翻译细胞疗法，是免疫学成功的关键 程序。共济会癌症中心还通过招聘新的教员来加强项目活动 以及为4个试点项目提供资金，这些项目产生了3笔NCI资助的赠款和总计450万美元的投资回报。MCC 支助和资助21个月的研讨会，其中包括5名受邀的外部发言者。广泛性 定期进行中的研究加强了方案内和方案间的互动 超级小组会议，仅限教职员工参加的数据俱乐部，期刊俱乐部，以及由共济会赞助的年度静修 癌症中心。项目成员还在培训下一代癌症患者方面发挥着领导作用 研究人员。免疫学项目的研究与共济会癌症中心的战略一致 科学优先发展(SPG1)，以扩大免疫疗法和细胞疗法的最新发现 包括实体瘤。此外，该项目的研究还解决了髓系细胞率升高的问题 明尼苏达州的白血病和黑色素瘤以及开发新的治疗方法来降低癌症发病率和 MN中主要癌症负担的死亡率：前列腺癌、乳腺癌、肺癌。